Pantoprazole (Protonix) tablets are currently in short supply. WellDyneRx therefore may be unable to fulfill member requests for this medication, and any affected members will be notified. Pantoprazole (Protonix) is a commonly used medication and currently ranks number 26 based on prescription volume and utilization.

WellDyneRx will work with members and pharmacies to allow retail fills if the member is able to find the medication locally before we are able to fulfill via mail order. Once the product becomes available in our pharmacy, we will promptly fulfill outstanding orders.

If affected, members have two options available:

  • They can try an over-the-counter product such as Prilosec OTC, Prevacid OTC or Nexium 24 OTC. These products all work in a similar way to pantoprazole.
  • They can contact their doctor and request a new prescription for a different medication in this category. Alternatives include omeprazole, lansoprazole, rabeprazole, Nexium, and Dexilant. These medications require a new prescription from their prescriber and therefore we cannot automatically substitute them.

We apologize for any inconvenience you experience if you are affected by this shortage.



Omega-3-acid ethyl esters capsules, the generic form of Lovaza, are currently in short supply. WellDyneRx is therefore currently unable to fulfill member requests for this medication. Once the product becomes available in our pharmacy, we will promptly fulfill outstanding orders.

In the interim, members have three options available:

  • They can purchase the brand form of the medication (Lovaza), which may require a higher copay.
  • They can speak with their prescribing doctor about whether replacement with a different type of prescription medication would be appropriate, or they should wait until the medication becomes available.
  • Speak to their physician or local pharmacist about whether an over-the-counter omega 3/fish oil product is appropriate until the medication becomes available.

We apologize for this inconvenience and will expedite order fulfillment as soon as this product is available to us.


Important Notice about Hydrocodone Combination Products

Effective October 6, 2014, all hydrocodone combination products (HCPs) will become schedule II drugs, according to a new rule from the Drug Enforcement Administration. This will affect pain-relief products with hydrocodone and acetaminophen, such as Vicodin® and Norco®, and cough syrups such as Tussionex®. Here are some important points about this change:

  • Prescriptions for HCPs written before October 6, 2014, are valid for six months (through April 8, 2015). This means that pharmacies can refill HCPs after October 6, 2014, if the prescription was issued before October 6, 2014, and the medication is refilled before April 8, 2015.
  • Prescribers will not be able to order refills for HCPs; however, they will be allowed to provide multiple prescriptions for up to a 90-day supply total.
  • HCPs may not be transferred from one pharmacy to another.
  • Prescribers will not be able to fax or phone in prescriptions for HCPs; however, they can e-prescribe. For immediate processing, have your prescriber use the following information to submit an e-prescription:

WellDyneRx CO
NCPDP ID # 0614708
PO Box 4517
Englewood, CO 80155
WellDyneRx FL
NCPDP ID #: 1035371
PO Box 90369
Lakeland, FL 33804

Please Note:WellDyneRx operates mail order facilities in Colorado and Florida. It does not matter which location your prescriber chooses when submitting a prescription.

FDA Questions Effectiveness of Two Generic Versions of Concerta

Two generic versions of methylphenidate hydrochloride extended-release tablets, the generic form of Concerta® used to treat attention-deficit disorder and attention-deficit hyperactivity disorder in adults and children may not work as effectively as the brand-name product according to a recent report released by the U.S Food and Drug Administration (FDA). After an investigation into adverse event reports submitted by physicians and patients and data previously provided by the manufacturers and independent FDA lab tests, the FDA concluded the generic products made by Mallinckrodt and Kudco, which are intended to be released in the body over a 10 to 12 hour period, were actually delivering the medication at a slower rate, closer to the 7 to 12 hour rate. This slower release rate means the drug may be less effective.

As a result of these findings the FDA has reclassified the therapeutic equivalence rating for the generic products manufactured by Mallinckrodt and Kudco from an AB rating to a BX rating. This means pharmacists can no longer automatically substitute these generics if a prescriber writes a prescription for brand-name Concerta. The generic version of Concerta manufactured by Actavis was found to be bioequivalent and is still classified as an AB rated generic.

There are no current safety concerns associated with these two generic versions of Concerta and patients should not make changes in their medication regimen before speaking with their doctor. The FDA has given Mallinckrodt and Kudco six months to confirm the effectiveness of their products or withdraw from the market.

Reference Melthylphenidate Hydrochloride Extended Release Tablets (generic Concerta) made by Mallinckrodt and Kudco. Accessed November 19, 2014.

Bookmark this site
Copyright 2014 by WellDyneRx